NCT05651880View on ClinicalTrials.gov

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2026

Conditions
Active Non-anterior Non-infectious Uveitis
Interventions
DRUG

Baricitinib 4 MG

4 mg per day for 6 months (For patients with creatinine clearance between 30 and 60 mL/min at baseline or during the study, the dosage of baricitinib will be 2 mg daily)

All Listed Sponsors
lead

University Hospital, Rouen

OTHER

NCT05651880 - Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis | Biotech Hunter | Biotech Hunter